Subscribe to continue reading
Subscribe to get access to the rest of this post and other subscriber-only content.
Subscribe to get access to the rest of this post and other subscriber-only content.
The CMA’s write-up of its Phase 1 decision regarding the joint venture between Forfarmers and Boparan raises several important points relevant to parties assessing merger control prospects, including :
The CMA identified horizontal and vertical competition concerns.
The deal has been abandoned shortly after reference to a Phase 2 investigation.
Last week the CMA announced that it has provisionally found so-called ‘vertical’ competition problems with the Microsoft/Activision deal, centring on the popular game ‘Call of Duty’.
A vertical problem is one that results from of the coming together – or greater coming together – of different levels in a supply chain, rather than a combination at the same level.
In the past few days there has been a lot of commentary on last week’s announcement, some of it suggesting that this case is somehow unique or unusual.
So – How unusual is this outcome?
As always, it depends how you measure it. But here are a couple of thoughts………
1……………..
This case is one of 14 where the Phase 1 investigation identified vertical competition problems sufficient to justify reference to an in-depth Phase 2 investigation.
To put this is context, there have been around 90 completed CMA Phase 2 investigations to date.
Five of the previous thirteen survived the CMA process.
This is a very similar survival rate to other Phase 2 cases
2………….
In my assessment, the Microsoft/Activision CMA Phase 2 investigation is one of eight to focus primarily or exclusively on vertical matters.
If the CMA decided to prohibit the current transaction it would mean that three of the eight did not survive the CMA process.
If, instead, the CMA accepted a remedy to the competition problems identified, this would the first among these eight cases.
————————–
There may well be other ways of looking at the question of how distinctive this case is.
Do comment below or drop me a line if you have other perspectives.
This post builds on data from a briefing on this case held in the first week of the year which also looked at the detail of the Phase 2 process and the significance of the extension to the Phase 2 timetable.
Here are links to some of the most insightful merger control articles I’ve come across so far this year:
1.
In this article Scott Sher discusses a number of matters that are highly pertinent in the UK as well as in the US, the focus of the piece.
2.
Will pressure on disposable incomes affect the CMA’s priorities in terms of which mergers it looks at?
James Baker and colleagues look at this question here.
3.
What can we learn from the two fast-track CMA Phase 2 remedy cases to date?
Sofia Platzer and colleagues take a look here.
4.
The future of merger remedies.
In this piece John Davies reports on the main themes of a recent conference on the subject
5.
The first year of the National Security and Investment Act
Kate Kelliher and Marc Israel review what happened in 2022. Link here.
Please feel free to add a comment or press the ‘like’ button if you’d like more of these occasional round-ups.